Program
saruparib
Also written as “Saruparib”, “Saruparib (AZD5305)” and “AZD5305”.
Its studies are mostly in Prostatic Neoplasms · Ovarian Neoplasms · Breast Neoplasms · Neoplasm Metastasis · Neoplasms, led by AstraZeneca.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 1411 open or running | phase 3since Oct 17, 2023 | Jul 30, 2014 | Dec 31, 2026phase 1 · NCT06713369 |
- Named in AstraZeneca’s own pipeline as
saruparib
, phase 3, as of Oct 30, 2026 (source).
Also a collaborator on its studies: fortrea, parexel and Bayer.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 1 study since Jul 30, 2014.
- Oct 26, 2020Phase 2 study in Ovarian NeoplasmsNCT04644068 · 702 enrolled · United States, Australia, Canada and more
- Oct 13, 2021Phase 2 study in Breast NeoplasmsNCT05123482 · 460 planned · United States, Australia, Belgium and more
- Apr 19, 2022Phase 2 study in Prostatic NeoplasmsNCT05367440 · 174 enrolled · United States, Australia, Italy and more
- Oct 7, 2022Phase 1 study in NeoplasmsNCT05573724 · 16 enrolled · Moldova, Republic of, Romania
- May 16, 2023Phase 1 study in Prostatic NeoplasmsNCT05938270 · 113 enrolled · United States, Australia, Canada and more
- Oct 17, 2023Phase 3 study in Prostatic NeoplasmsNCT06120491 · 1,898 enrolled · United States, Australia, Austria and more
- Mar 25, 2024Phase 3 study in Advanced Breast CancerNCT06380751 · 788 planned · United States, Argentina, Australia and more
- Jul 30, 2024Phase 1 study in Neoplasm MetastasisNCT06713369 · 8 planned · United Kingdom
- Mar 21, 2025Phase 1 study in Advanced Solid MalignanciesNCT06899061 · 41 enrolled · Bulgaria, Moldova, Romania
- Apr 30, 2025Phase 3 study in Prostatic NeoplasmsNCT06952803 · 700 planned · United States, Argentina, Australia and more
- Jun 24, 2025Phase 2 study in Ovarian NeoplasmsNCT07060365 · Spain
- Feb 26, 2026Phase 2 study in Solid TumoursNCT07446855 · 180 planned · United States, Australia, Japan and more
- Jul 14, 2026Phase 3 study in Prostatic NeoplasmsNCT07711002 · 1,330 planned · United States, Austria, Brazil and more
- Nov 12, 2026Primary completion moved from 2026-10-02 to 2026-12-31Date moved laterphase 1 · +3 months · NCT06713369
Ahead
- Dec 31, 2026Primary completion: phase 1 study in Neoplasm MetastasisNCT06713369
- May 28, 2027Primary completion: phase 2 study in Ovarian NeoplasmsNCT04644068
- Sep 29, 2027Primary completion: phase 2 study in Breast NeoplasmsNCT05123482
- Sep 30, 2027Primary completion: phase 3 study in Prostatic NeoplasmsNCT06120491
TargetBeta
“An orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP), with potential chemo/radiosensitizing and antineoplastic activities. Upon administration, saruparib selectively targets and binds to PARP and prevents PARP-mediated DNA repair of single-strand DNA breaks vi…”NCIt, read by Claude
“Saruparib (AZD5305) is a potent and selective inhibitor of PARP1, with minimal effect on PARP2.”study text, by rule · the study
Other programs on the same two targets
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07711002Prostatic Neoplasms · United States, Austria, Brazil and more | 3 | Recruiting | May 30, 2031 | 1,330 |
| NCT07446855Solid Tumours · United States, Australia, Japan and more | 2 | Recruiting | Mar 29, 2030 | 180 |
| NCT07060365Ovarian Neoplasms · Spain | 2 | Withdrawn | Dec 19, 2025 | 0 |
| NCT06952803Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Recruiting | Mar 31, 2033 | 700 |
| NCT06899061Advanced Solid Malignancies · Bulgaria, Moldova, Romania | 1 | Active, not recruiting | Feb 3, 2026 | 41 |
| NCT06713369Neoplasm Metastasis · United Kingdom | 1 | Recruiting | Dec 31, 2026 | 8 |
| NCT06380751Advanced Breast Cancer · United States, Argentina, Australia and more | 3 | Recruiting | Dec 18, 2029 | 788 |
| NCT06120491Prostatic Neoplasms · United States, Australia, Austria and more | 3 | Active, not recruiting | Sep 30, 2027 | 1,898 |
| NCT05938270Prostatic Neoplasms · United States, Australia, Canada and more | 1 | Completed | Jun 15, 2026 | 113 |
| NCT05573724Neoplasms · Moldova, Republic of, Romania | 1 | Completed | Apr 17, 2023 | 16 |
| NCT05367440Prostatic Neoplasms · United States, Australia, Italy and more | 2 | Active, not recruiting | Apr 11, 2031 | 174 |
| NCT05123482Breast Neoplasms · United States, Australia, Belgium and more | 2 | Recruiting | Sep 29, 2027 | 460 |
| NCT04644068Ovarian Neoplasms · United States, Australia, Canada and more | 2 | Active, not recruiting | May 28, 2027 | 702 |
| NCT02264678Ovarian Neoplasms · United States, France, South Korea and more | 1 | Active, not recruiting | Mar 4, 2025 | 358 |
How it is read
Names in the registry
- “Saruparib”, 6 entries
- “Saruparib (AZD5305)”, 3 entries
- “AZD5305”, 3 entries
- “[14C]-AZD5305 microtracer”, 1 entry
- “[14C]-AZD5305 (therapeutic dose)”, 1 entry
Codes read as this program: AZD5305.
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 5 studies
- Ovarian Neoplasms, 3 studies
- Breast Neoplasms, 2 studies
- Neoplasm Metastasis, 1 study
- Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.